Recurrent Oropharyngeal Squamous Cell Carcinoma Active Not Recruiting Phase 1 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0037158 (Recurrent Oropharyngeal Squamous Cell Carcinoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01254617Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck CancerTreatment